Logo image
Raising the Hemostatic Bar in Hemophilia A: The Promise of Mim8
Letter/Communication

Raising the Hemostatic Bar in Hemophilia A: The Promise of Mim8

Anjali A Sharathkumar
NEJM clinician (Online)
05/20/2026
DOI: 10.1056/CLINjwNA60116

View Online

Abstract

Clinical Takeaway Mim8, a bispecific antibody similar to emicizumab, offers prophylactic efficacy with convenient subcutaneous dosing.
Disease Prevention Hemophilia FDA approval

Details

Metrics

1 Record Views
Logo image